Your session is about to expire
← Back to Search
Other
Intravenous Fluids in Adults With Diabetic Ketoacidosis in the Emergency Department (BRISK-ED Trial)
N/A
Waitlist Available
Led By Justin W Yan, MD, MSc
Research Sponsored by London Health Sciences Centre Research Institute and Lawson Research Institute of St. Joseph's
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up one year
Awards & highlights
No Placebo-Only Group
Summary
This trial is testing whether Ringer's Lactate, a type of IV fluid, can help adults with diabetic ketoacidosis (DKA) recover faster than the commonly used normal saline. Ringer's Lactate is thought to be more balanced and less likely to increase blood acidity. If successful, this could lead to shorter hospital stays and better outcomes for patients. Ringer's Lactate has been studied as an alternative to normal saline for various conditions, including diabetic ketoacidosis, due to its balanced electrolyte composition and lower risk of causing acidosis.
Eligible Conditions
- Diabetic Ketoacidosis
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ one year
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~one year
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Patient recruitment rate (feasibility outcome)
Time to DKA resolution (efficacy outcome)
Secondary study objectives
Hospital length of stay
Hyper- or hypo-kalemia post-emergency department
In-hospital acute kidney injury (Stage 2 or greater) post-emergency department
+4 moreAwards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: Ringer's lactateExperimental Treatment1 Intervention
The intervention is administration of IV Ringer's lactate. Rate of study fluid will be at the treating physician's (both ED and inpatient, if consulted for admission) discretion. Apart from fluid administered, there will be no other changes to the patient's clinical care, and patients will receive standard DKA treatment which may include insulin, electrolyte replacement, and/or supportive management. Pharmacy-prepared kits of 8 x 1L bags of study fluid (in Self et al., a maximum of 7090mL was given8) will be kept in a secure space within the ED. Once packaged, IV bags are useable for 30 days before expiration. If a kit is opened but not used completely, individual 1L bags may be returned to the pharmacy to save on costs.
Group II: Normal salineActive Control1 Intervention
The comparator is administration of IV normal saline. Rate of study fluid will be at the treating physician's (both ED and inpatient, if consulted for admission) discretion. Apart from fluid administered, there will be no other changes to the patient's clinical care, and patients will receive standard DKA treatment which may include insulin, electrolyte replacement, and/or supportive management. Pharmacy-prepared kits of 8 x 1L bags of study fluid (in Self et al., a maximum of 7090mL was given8) will be kept in a secure space within the ED. Once packaged, IV bags are useable for 30 days before expiration. If a kit is opened but not used completely, individual 1L bags may be returned to the pharmacy to save on costs.
Find a Location
Who is running the clinical trial?
London Health Sciences Centre Research Institute and Lawson Research Institute of St. Joseph'sLead Sponsor
571 Previous Clinical Trials
401,433 Total Patients Enrolled
Lawson Health Research InstituteLead Sponsor
683 Previous Clinical Trials
431,368 Total Patients Enrolled
Justin W Yan, MD, MScPrincipal InvestigatorLawson Health Research Institute/Western University